Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF(159506.SZ)

Company Encyclopedia
View More
name
Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF
159506.SZ
News
View More

Hansoh Pharma Wins Fifth China Approval for Flagship Lung Cancer Drug Ameile

Hansoh Pharmaceutical Group has received its fifth approval in China for its lung cancer drug Ameile, allowing its use in combination with chemotherapy for adults with specific EGFR mutations. This approval enhances Ameile's clinical applications and strengthens Hansoh's position in the oncology market. The stock is rated a Buy with a target price of HK$48.20, and the company is expanding its international presence following UK approval.

Tip Ranks·
HK
03692
+2.11%
Tip Ranks·
HK
03692
+2.11%

WuXi AppTec Grants Awards Under 2024 H Share Award and Trust Scheme

WuXi AppTec Co. Ltd. has granted 126,240 underlying H Share Award Shares to 24 participants under its 2024 H Share Award and Trust Scheme, representing about 0.0247% of total issued H Shares. The vesting of these awards is contingent on individual performance indicators and other specified conditions.

Reuters·
SH
603259
+0.93%
HK
02359
-0.98%
Reuters·
SH
603259
+0.93%
HK
02359
-0.98%

Zai Lab’s Augtyro receives NMPA approval for solid tumours in China

Zai Lab has received approval from China's NMPA for Augtyro (repotrectinib) to treat adult patients with solid tumours harboring an NTRK gene fusion. This approval is based on the Phase I/II TRIDENT-1 study, demonstrating durable efficacy and manageable safety. Augtyro is now approved for patients with metastatic or locally advanced disease who have progressed on prior therapies. Zai Lab holds exclusive rights to develop and commercialize Augtyro in mainland China and other regions through a license agreement with Bristol Myers Squibb.

Pharmaceutical Technology·
US
ZLAB
+0.27%
HK
09688
-1.69%
Pharmaceutical Technology·
US
ZLAB
+0.27%
HK
09688
-1.69%

WuXi AppTec faces another reduction in holdings by its major shareholder, with a cumulative cash-out of nearly 20 billion over 3 years

WuXi AppTec's controlling shareholder reduced their holdings by approximately 59.68 million shares between November 20, 2025, and January 5, 2026, cashing out nearly 20 billion yuan in total. This reduction was transferred to a well-known international investor, with the selling price ranging from 84.66 to 95.08 yuan per share, amounting to 5.4 billion yuan. After the reduction, the controlling shareholder's stake decreased to 16.211%. Affected by geopolitical factors and market fluctuations, WuXi AppTec's stock price rose over 90% by the end of 2025, but has recently seen a pullback. On January 7, the stock price slightly dropped to 98.41 yuan per share

Stheadline·
SH
603259
+0.93%
HK
02359
-0.98%
Stheadline·
SH
603259
+0.93%
HK
02359
-0.98%

Akeso's Ivonescimab Shows Significant Survival Benefits in HARMONi-A Phase III NSCLC Trial

Akeso Inc. announced a significant label update for its bispecific antibody, ivonescimab, after approval by China's National Medical Products Administration. The update is based on the HARMONi-A Phase III trial, showing significant improvements in progression-free survival (PFS) and overall survival (OS) for patients with advanced non-squamous non-small cell lung cancer (nsq-NSCLC) post-EGFR-TKI therapy. The final analysis indicated a 26% reduction in death risk and a 54% reduction in disease progression risk compared to chemotherapy alone. Ivonescimab is now included in China's National Reimbursement Drug List for specific NSCLC indications.

Reuters·
HK
09926
-0.47%
Reuters·
HK
09926
-0.47%
© 2026 Longbridge｜Disclaimer